WPATH

The New England Journal of Medicine continues to besmirch its once august reputation by pushing ideology rather than medical science when discussing our nation’s most contentious social issues. This is particularly true about so-called gender-affirming care for minors experiencing gender confusion. Even as repeated medical studies undercut the ideological narrative that puberty blockers, hormones, and even surgeries are the best means of caring for dysphoric children — and as country after country severely restricted those interventions — (with the exception of an unsubstantive criticism of the Cass Review) articles in the NEJM on the question usually pretend that the pushback never happened.

Now, the editors have done it again, publishing an article by Scott Skinner-Thompson, an LGBT activist law professor from the University of Colorado, Boulder, criticizing the Supreme Court for allowing Tennessee to legally prevent such interventions in children. The pretense begins with the headline, “The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors.” To the contrary, Tennessee and other jurisdictions that have enacted such laws have done so to protect trans minors from potentially irreversible harm, in the knowledge that most gender dysphoric minors overcome their confusion by the time they reach adulthood.

Then, Skinner-Thompson leans on clearly ideological opinions by medical associations, despite at least one of which (WPATH) having been substantively discredited:

On June 18, 2025, the U.S. Supreme Court upheld Tennessee’s ban on gender-affirming hormonal treatment for transgender minors against an Equal Protection Clause challenge in United States v. Skrmetti. Transgender adolescents who need these medical interventions but live in one of the many states that ban them may need to look elsewhere for care. Nearly every major relevant U.S. health care organization has concluded that the prescription of hormones and puberty blockers for treating gender dysphoria in transgender adolescents is often medically appropriate in that it can improve mental health and well-being, whereas untreated gender dysphoria can lead to depression, anxiety, and suicidality.

As many Western countries reverse their former embrace of so-called “gender-affirming care” as it applies to children, the American medical establishment has obstinately pretended that puberty blockers and transition surgeries are medically uncontroversial. The latest example: An advocacy article published in the February 12, 2025 New England Journal of Medicine — yet again — decrying laws passed to protect children from transition interventions. From “Advancing Transgender Health amid Rising Policy Threats” (citations omitted): Gender-affirming care is a cornerstone of multidisciplinary health support for transgender and nonbinary people; it is widely recognized as essential, evidence based, and often lifesaving. The standards of care issued by the World Professional Association for Transgender Health emphasize the critical role of interventions such as pubertal Read More ›

Fresh off publishing an unsubstantial attack on the Cass Review that recommended against puberty blockers for gender dysphoric youth, the New England Journal of Medicine offers an advocacy piece demanding that prisoners claiming to be transgender be given free “transition surgeries.” From “Gender-Affirming Surgical Care in Carceral Settings“: Several U.S. courts have held that access to gender-affirming care during incarceration is a trans person’s right. This conclusion is reflected in the Federal Bureau of Prisons (BOP) clinical guidance, which governs clinical care provision within federal carceral facilities, which house an estimated 1200 trans people. The BOP, whose guidance often sets the standard for health care delivery in state and local carceral facilities, recommends provision of gender-affirming care during incarceration, including Read More ›

It is increasingly clear that there is little scientific basis for administering puberty blockers to gender-dysphoric youth. Consequently, many European countries have now effectively banned their use outside of official studies. Now, the New Zealand Ministry of Health has similarly found that there is a “dearth” of evidence supporting blocking normal adolescence in youngsters who feel that their gender is different from their sex. The New Zealand study reviewed all the literature on the question published before September 30, 2023. In other words, it was a study of the findings of published studies. First, it found that studies claiming that puberty blockers helped ease depression were of very poor quality. From “Impact of Puberty Blockers in Gender-Dysphoric Adolescents” (my emphasis): Impact of puberty blockers on Read More ›